Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CITIZIN
- Development stage
- Unknown
- Lead developer
- Bruschettini
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CITIZIN is an ophthalmic nutraceutical developed by Bruschettini. It is formulated as an oral solution in single-dose sachets and is designed to support visual function and maintain the structural and functional integrity of retinal ganglion cells and photoreceptors. The primary active component of CITIZIN is citicoline (Cognizin), a metabolic precursor in the biosynthesis of phosphatidylcholine and other membrane phospholipids. CITIZIN is also enriched with vitamins A, C, E, B-complex vitamins (B1, B2, B6, B12, biotin), and blackcurrant extract, which collectively provide neuroprotective, antioxidant, and microcirculatory support. It is primarily used as a dietary supplement to manage ophthalmic conditions such as glaucoma and optic neuropathies.
- Brand names
- CITIZIN
Beyond the preview
Go deeper on CITIZIN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CITIZIN.